What is the market's earnings forecast for Tarsus next quarter?

What were the key takeaways from Tarsus's earnings call?

What were the key takeaways from Tarsus’s earnings call?

What is Tarsus's latest dividend and current dividend yield?

What is Tarsus's gross profit margin?

What guidance did Tarsus's management provide for the next earnings period?

What is the revenue and EPS growth rate for Tarsus year over year?

Did Tarsus beat or miss consensus estimates last quarter?

- **$2B Peak Sales Ambition**: XDEMVY targeting $2B U.S. peak sales by 2030+ on 25M DB patients, with 0.5M treated to date.
- **Pipeline Momentum**: 
  - Ocular rosacea Phase II trial underway, Lyme disease prevention trial launching Q2 2026.
  - Global expansion with TP-03 approvals in Japan (2025), Europe (2027).
- **2026 Growth**: $670-700M net sales (+50% YoY), driven by DTC (25% patient awareness) and 15-20 new sales reps.
- **Financial Discipline**: Gross margin ~93%, 2026 R&D spend ~$25M for key trials.

**【CEO Summary Section】**
- Tarsus achieved $451.4 million in full-year 2025 net sales, with XDEMVY treating over 0.5 million patients for Demodex blepharitis (DB). 
- XDEMVY is on track to exceed $2 billion in peak U.S. sales, driven by 25 million addressable patients and 15-18 million ocular rosacea sufferers.
- The company is expanding its pipeline with two clinical-stage programs: TP-04 for ocular rosacea (Phase II trial starting Q4 2025) and TP-05 for Lyme disease prevention (Phase II trial Q2 2026).
- 2026 net sales guidance: $670-700 million (+50% YoY), with Q1 expected to be flat/declining due to seasonal factors.

**【CFO Financial Commentary】**
- Q4 2025 net product sales: $151.7 million (gross-to-net 44%). Full year: $451.4 million (gross-to-net 45%).
- 2026 operating expenses: 
  - SG&A: $545-565 million (includes $80M DTC spend, 15-20 new sales reps)
  - R&D: $115-135 million (TP-04: $7-10M, TP-05: $25-30M)
- Gross margin expected to remain ~93% as XDEMVY becomes profitable and scalable.

**【Pipeline Updates】**
- **Ocular Rosacea (TP-04):** Phase II trial launched Q4 2025 to evaluate erythema/telangiectasia endpoints. Topline data expected Q1 2027.
- **Lyme Disease (TP-05):** Phase II trial to enroll 700 high-risk patients Q2 2026. Topline data Q1 2027.
- Global expansion: TP-03 expected to launch in Japan 2026, Europe 2027, and China 2025.

**【Q&A Highlights】**
- **Seasonality:** Q1 2026 sales expected flat/slightly down vs Q4 2025 due to deductible resets. Q2-Q4 growth driven by DTC awareness (25% patient recognition) and refill rates (~15% now → 20% steady state).
- **DTC Efficiency:** Maintaining $80M annual spend despite positive ROI, as prescribers need support converting DTC leads.
- **Ex-US Potential:** Japan, Europe, China markets similar to U.S. with ~10% ex-US sales contribution long-term.
- **Patent Protection:** TP-03 patents extend to 2040, supporting long-term value.


Tarsus Pharmaceuticals, Inc.(TARS)-20260224-2025 Q4 Earnings call transcript

- **Q3 Growth Records**: $119M revenue, 147% YoY growth, 103,000 bottles dispensed, and 20,000+ prescribers highlight XDEMVY's market dominance.
- **Pipeline Momentum**: Phase II for ocular rosacea (TP-04) and Lyme disease prevention (TP-05) on track, with global expansion plans.
- **Sustainability Signals**: 10% weekly refills, 44.7% gross-to-net discount stability, and DTC campaign ROI exceeding expectations.
- **Strategic Focus**: Scaling commercial engine for 25M+ DB sufferers, with 1.6% penetration to date.

**【CEO Summary Section】**
- XDEMVY achieved $119 million in net revenue and 103,000 bottles dispensed in Q3, up 147% year-over-year. Over 20,000 doctors have prescribed XDEMVY, with weekly prescribers increasing by 20% and multiple-times-a-week prescribers up 30%.
- XDEMVY is becoming a standard treatment for Demodex blepharitis (DB), with doctors expanding use across conditions like dry eye, cataracts, and contact lens intolerance. Patient-driven demand via DTC campaigns is driving new prescriptions.
- Pipeline progress includes Phase II for ocular rosacea (TP-04) and Lyme disease prevention (TP-05), with global expansion plans for Europe and Japan.

**【CCO Financial & Commercial Update】**
- Q3 gross-to-net discount was 44.7%, stable vs. Q2, driven by Medicare dynamics. Refill rates reached 10% weekly and 15-20% annually, aligning with long-term expectations.
- Direct-to-consumer (DTC) campaign delivered 90% increase in website visits and 42% rise in unaided brand awareness, with positive ROI exceeding expectations.
- Commercial engine is scaling with 400,000+ patients treated, but only 1.6% of the 25 million estimated DB sufferers, indicating significant growth potential.

**【CFO Financial Commentary】**
- Q4 net product sales guidance: $140-145 million (annualized $440-445 million). Gross-to-net discount expected to remain 43-45% due to Medicare mix.
- Operating expenses for 2025 will reach the top of the $70-80 million DTC spend range. Ocular rosacea Phase II costs ($7-10 million) and Lyme disease Phase IIb decisions will shape 2026 OpEx.

**【Q&A Highlights】**
- **Prescribing Patterns**: Doctors are integrating XDEMVY into routine care for multiple conditions, citing DB's impact on surgical outcomes and visual fluctuations.
- **Refill Dynamics**: 10% weekly refills and 15-20% annualized rates align with expectations, driven by chronic disease management education.
- **Pipeline Clarity**: TP-04 Phase II for ocular rosacea will measure telangiectasia and erythema reduction, leveraging TP-04's proven efficacy in papulopustular rosacea.
- **Market Segmentation**: Optometrists (65% of scripts) focus on in-clinic medical management, while ophthalmologists target cataract patients with DB comorbidities.


Tarsus Pharmaceuticals, Inc. (TARS) Q3 2025 Earnings Call Transcript

- **Q2 Record Sales**: $102.7 million net sales, 30% sequential growth, 20,000+ prescribers, and 90% payer coverage.
- **DTC Campaign Success**: Unaided awareness tripled, website interactions +400%, weekly prescribers at 1/3 of core audience.
- **Expanded Peak Potential**: Exceeds $1 billion, driven by 25 million U.S. DB patients and expanding use cases.
- **Financial Strength**: $381 million cash, Q3 guidance of 95,000-100,000 bottles, and low 40s% gross-to-net by year-end.
- **Pipeline Momentum**: TP-04 Phase II late 2025, XDEMVY global expansion, and 20% annualized retreatment rate target.

**【CEO Summary Section】**
- Q2 2025 net sales reached $102.7 million, with 91,000 bottles dispensed, marking a 30% sequential growth. XDEMVY is driving a new category in eye care, with 20,000 prescribers and 90% payer coverage.
- Direct-to-consumer (DTC) campaign success: unaided awareness tripled, website interactions up 400%, and weekly prescribers at 1/3 of core audience. Peak potential now exceeds initial $1 billion+ projection.
- Pipeline momentum: TP-04 for ocular rosacea (OR) Phase II study expected late 2025, with global expansion plans for XDEMVY in Japan and Europe.

**【CFO Financial Commentary】**
- Q2 gross margin 93%, with SG&A expenses $44 million (up 30% YoY) due to DTC and sales force expansion. R&D expenses increased $3.3 million for TP-04.
- Q3 guidance: 95,000-100,000 bottles dispensed, gross-to-net discount improving to low 40s% by year-end. DTC spend maintained at $70-80 million annually.
- Cash reserves $381 million, supporting long-term growth and pipeline development.

**【Q&A Key Highlights】**
- **Prescriber Growth**: 20,000+ prescribers (60% optometry, 40% ophthalmology), with no erosion in core base. DTC campaign to continue through 2025, with spend steady-state.
- **Gross-to-Net**: Low 40s% steady-state expected post-2025, driven by declining patient copays.
- **Peak Potential**: Exceeds $1 billion, fueled by 25 million U.S. DB patients and expanding use cases (e.g., cataract surgery prep).
- **Retreatment Rates**: Target 20% annualized, currently 10%+ and trending up. TAM focus on 9 million high-risk patients.
- **OR Pipeline**: Phase II study on track for late 2025, with $7-10 million R&D spend split 2025-2026.

Tarsus Pharmaceuticals, Inc. (TARS) Q2 2025 Earnings Call Transcript

- **XDEMVY super growth**: Q1 sales $78.3M (+217% YoY), 72,000 bottles dispensed.
- **Global expansion momentum**: Japan regulatory meetings H2 2025, Europe approval 2027.
- **Ocular Rosacea pipeline**: TP-04 Phase 2 start late 2025, $7-10M R&D spend.
- **DTC spend boost**: $70-80M annual budget, Q2 incremental spend $5-10M.
- **Financial strength**: $407.9M cash post-upsize equity raise.


**【CEO Opening Remarks】**
- Q1 2025 XDEMVY net sales reached $78.3 million, up 217% YoY, driven by 72,000 bottles dispensed to patients.
- Global expansion plans include Japan (potential regulatory meetings H2 2025) and Europe (targeting 2027 approval).
- TP-04 for Ocular Rosacea expected to initiate Phase 2 trial late 2025, with $7-10 million R&D costs split between 2025-2026.
- Recent $135 million equity raise strengthens financial position for pipeline advancement.

**【CFO Financial Highlights】**
- Gross to net discount rate: 47% (Q1 2025) vs. 48% (Q4 2024), reflecting strong payer coverage.
- Operating expenses: $104.6 million (Q1 2025), up 14% QoQ due to DTC advertising.
- Cash balance: $407.9 million post-equity raise, supporting 2025 DTC spend of $70-80 million.
- Q2 2025 outlook: 85,000-90,000 bottles dispensed, 45-47% gross to net discount.

**【Commercial Execution】**
- Expanded sales force driving 110% increase in weekly prescribers vs. Q3 2024.
- 90%+ commercial/Medicare coverage eliminates access barriers.
- DTC campaign boosts website traffic +140% QoQ, with network TV expansion.
- Medicare prescriptions now ~50% of total volume post-coverage activation.

**【Pipeline Progress】**
- Ocular Rosacea: TP-04 gel formulation targeting Demodex mites, with Phase 2 design finalized.
- Japan market potential validated by DB prevalence data comparable to US levels.
- Europe: XDEMVY approval path confirmed without Phase 3 trial requirement.

**【Q&A Key Takeaways】**
- FDA pipeline meetings proceeding as scheduled, no delays reported.
- DTC campaign ROI tracking above expectations, with $5-10 million incremental Q2 spend.
- Retreatment rates aligning with 20% annualized target, supported by Phase 3 follow-up data.
- Channel inventory stable at 2.5 weeks, no stocking risk identified.


Tarsus Pharmaceuticals (TARS)-1 May 25-2025 Q1 Earnings call transcript

- **XDEMVY Success**: $180M in 2024 sales, 15,000+ prescribers, 90% coverage.
- **Pipeline Momentum**: TP-04 Phase II (ocular rosacea) and TP-05 Lyme guidance.
- **DTC Growth**: $60-70M annual ad spend to drive patient engagement.
- **Financial Strength**: $291M cash, 2025 Q1 sales guidance of 62-67K bottles.
- **Prescription Trends**: Doctors moving to weekly/daily prescribing based on results.

**【CEO Opening Remarks】**
- Tarsus achieved $180 million in net product sales for XDEMVY in 2024, with 163,000 bottles dispensed to patients.
- Expanded sales force to 150 representatives, resulting in 15,000+ ECPs prescribing XDEMVY.
- 90% of commercial and Medicare lives covered, with DTC ad campaign driving patient awareness.
- Announced Phase II trial for TP-04 (ocular rosacea) and FDA guidance for TP-05 (Lyme disease prevention).

**【CFO Financial Highlights】**
- Q4 2024 net product sales: $64.4 million; full year: $180.1 million.
- Gross margin: 93% (excluding royalty and milestones).
- 2025 guidance: $62-67 million bottles dispensed in Q1, with annual growth driven by expanded sales force and DTC campaign.
- DTC ad spend: $60-70 million annually, with $15 million allocated to Q1 2025.
- Cash reserves: $291.4 million at year-end.

**【Q&A Key Takeaways】**
- **Prescription Frequency**: Doctors moving from monthly to weekly/daily prescribing due to XDEMVY's efficacy and MGD data.
- **DTC Impact**: Early metrics show increased website engagement and patient-driven appointments, with full results expected in 2025.
- **Pipeline Costs**: Phase II TP-04 trial ($7-10 million) and TP-05 Phase III planning; Lyme disease program may seek partner for Phase III.
- **Gross to Net Discount**: Q1 2025 expected at 46-49%, improving to low 40s by year-end.
- **Lyme Disease Strategy**: Focused on prevention, with Phase IIa results showing >90% tick kill rate.

Actual	-0.68	0.475	0.29	-0.76	-0.72	-0.98	-0.24	-0.84	-0.46	-0.88	-1.17	-1.28	-1.31	-1.01	-0.88	-0.61	-0.6	-0.64	-0.48	-0.3	-0.2
Forecast	-0.6634	-0.2509	-0.46	-0.4174	-0.7464	-0.9033	-0.6422	-0.96	-0.668	-0.956	-1.079	-1.3504	-1.3721	-1.1809	-0.923	-0.9398	-0.743	-0.7299	-0.3786	-0.3494	-0.093
Surprise	-2.50%	+289.32%	+163.04%	-82.08%	+3.54%	-8.49%	+62.63%	+12.50%	+31.14%	+7.95%	-8.43%	+5.21%	+4.53%	+14.47%	+4.66%	+35.09%	+19.25%	+12.32%	-26.78%	+14.14%	-115.05%

TARS

TARS fundamentals

TARS Q4 2025 Earnings

Earnings Call

You can ask Aime

TARS

TARS fundamentals

TARS Q4 2025 Earnings

Earnings Call

TARS Earnings Call Summary for Q4/20254:30 PM on Feb 23, 2026

TARS Earnings Call Summary for Q3/20254:30 PM on Nov 4, 2025

TARS Earnings Call Summary for Q2/20254:30 PM on Aug 6, 2025

TARS Earnings Call Summary for Q1/20254:30 PM on May 1, 2025

TARS Earnings Call Summary for Q4/20248:00 AM on Feb 25, 2025

You can ask Aime